Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 401-408

  Nio, Yoshinori ^a   Hashimoto, Koji ^a   Yano, Seiji ^a   Itakura, Masayuki ^a   Koike, Makoto ^a   Yamaguchi, Kazushige ^a   Endo, Shinichiro ^a   Tsuji, Munechika ^a   Higami, Tetsuya ^a   Maruyama, Riruke ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; Gemcitabine; Pancreatic cancer; Radiotherapy; UFT

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; TEGAFUR; URACIL;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NAUSEA; ORAL DRUG ADMINISTRATION; PANCREAS TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIOTHERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CONSTIPATION; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; LEUKOPENIA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; RADIOTHERAPY; SURVIVAL RATE; TEGAFUR; THROMBOCYTOPENIA; TREATMENT OUTCOME; URACIL;

EID: 24744465646     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.401     Document Type: Article

References (34)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000. (Pubitemid 30072093)
2. Safioleas MC and Moulakakis KG: Pancreatic cancer today. Hepatogastroenterol 51: 862-868, 2004. (Pubitemid 38590983)
3. Nitecki SS, Sarr MG, Colby TV and van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221: 59-66, 1995.
4. Van Cutsem E, Aerts R, Haustermans K, Topal B, van Steenbergen W and Verslype C: Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 16: 265-274, 2004. (Pubitemid 38368369)
5. Okusaka T and Kosuge T: Systemic chemotherapy for pancreatic cancer. Pancreas 28: 301-304, 2004. (Pubitemid 38437328)
6. Pasetto LM, Jirillo A, Stefani M and Monfardini S: Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol 49: 135-151, 2004. (Pubitemid 38175440)
7. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
8. Heinemann V: Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 29 (Suppl. 3): 25-35, 2002.
9. Hidalgo M, Castellano D, Paz-Ares L, et al: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592, 1999. (Pubitemid 29075246)
10. Berlin JD, Adak S, Vaughn DJ, et al: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncol 58: 215-218, 2000. (Pubitemid 30189904)
11. Cascinu S, Frontini L, Labianca R, et al: A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian group for the study of digestive tract cancer (GISCAD). Ann Oncol 11: 1309-1311, 2000.
12. Kurtz JE, Kohser F, Negrier S, et al: Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterol 47: 1450-1453, 2000.
13. Oliani C, Padovani M, Barana D, et al: Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Res 24: 2107-2112, 2004. (Pubitemid 38954642)
14. Kanat O, Evrensel T, Kurt E, et al: Treatmen of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori 90: 192-195, 2004. (Pubitemid 38745607)
15. Novarino A, Chiappino I, Bertelli GF, et al: Phase II study of cisplatin. Gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 15: 474-477, 2004. (Pubitemid 38444552)
16. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002. (Pubitemid 34831525)
17. Ohta K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 323-328, 1988.
18. Sulkes A, Benner S and Canetta R: Uracil-tegafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16: 3461-3475, 1998. (Pubitemid 28481645)
19. Van Cutsem E and Peeters M: Oral fluoropyrimidines in colorectal cancer. Semin Oncol 27 (Suppl. 10): 91-95, 2000.
20. Ho DH, Pazdur R, Covington W, et al: Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetra-hyfrofuryl)- 5-fluorouracil. Clin Cancer Res 4: 2085-2088, 1998. (Pubitemid 28415651)
21. Ueno H, Okada S, Okusaka T, Ikeda M and Kuriyama H: Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncol 62: 223-227, 2002. (Pubitemid 34639055)
22. Feliu J, Lopez Alvarez MP, Jaraiz MA, et al: Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. Cancer 89: 1706-1712, 2000.
23. Feliu J, Mel R, Borrega P, et al: Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 13: 1756-1762, 2002. (Pubitemid 35446267)
24. Lee J, Park JO, Kim WS, et al: Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology 66: 32-37, 2004. (Pubitemid 38410677)
25. Nio Y: Chemotherapy of pancreatic cancer - adjuvant chemotherapy. (Article in Japanese). Consensus of cancer therapy 2: 28-31, 2003.
26. Iguchi C, Nio Y, Sato Y, et al: A case of recurrent ampullary carcinoma of the papilla of Vater in which a complete response was induced by combination therapy using radiotherapy and oral chemotherapy employing UFT and cyclophosphamide. (Article in Japanese). Jpn J Cancer Chemother 26: 1641-1645, 1999.
27. Minari Y, Nio Y, Endo S, et al: A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy. Jpn J Cancer Chemother 27: 121-125, 2000.
28. Okusaka T, Ito Y, Ueno H, et al: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91: 673-677, 2004. (Pubitemid 39141622)
29. NCI-CTC version 2.0. Common toxicity criteria - notice of modifications. (http://ctep.info.nih.gov/).
30. Fishman B, Pasternak S, Wallenstein SL, et al: The memorial pain assessment card: a valid instrument for the evaluation of cancer pain. Cancer 60: 1151-1158, 1987. (Pubitemid 17157235)
31. Gregory RK, Johnston SR, Smith IE and Miles D: UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. Oncology (Huntingt) (Suppl. 9) 14: 47-49, 2000.
32. Ogawa Y, Ishikawa T, Chung SH, et al: Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 23: 3453-3457, 2003. (Pubitemid 36975448)
33. Haga S, Shimizu T, Imamura H, et al: Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice. Anticancer Res 193A: 1791-1796, 1999. (Pubitemid 29392739)
34. Endo M, Sinbori N, Sawada N, Ishikawa T, Ishitsuka H and Tanaka Y: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83: 127-134, 1999. (Pubitemid 29409488)